FDA Approves First Generic Farxiga (dapagliflozin) Tablets

Medically reviewed by Judith Stewart, BPharm. Last updated on April 7, 2026.

April 7, 2026 -- The U.S. Food and Drug Administration approved the first generics of Farxiga (dapagliflozin) tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, and as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Farxiga is sodium-glucose cotransporter 2 (SGLT2) inhibitor that works by reducing the reabsorption of glucose and sodium in the kidneys.

Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It develops over many years and is usually diagnosed in adults. According to the Centers for Disease Control and Prevention, more than 40 million Americans have diabetes, and 90% to 95% of those individuals have type 2 diabetes.

The prescribing information for the generic dapagliflozin tablets includes the same contraindications, warnings and precautions as Farxiga. Dapagliflozin is contraindicated in patients with a history of a serious hypersensitivity reaction to dapagliflozin or any of the excipients. Dapagliflozin carries warnings such as diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis, and volume depletion. The most common side effects reported in the clinical trials for dapagliflozin were female genital mycotic infections, nasopharyngitis, and urinary tract infections

Healthcare providers should review the full prescribing information for complete safety and dosing information.

The FDA granted approval of dapagliflozin tablets to multiple generic drug applicants. Please check the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the “Orange Book”) for a complete list of approvals and contact the manufacturers for information about a medicine’s availability.

Farxiga is a registered trademark of the AstraZeneca group of companies.

Source: FDA

Source: HealthDay

Night Shifts Are Tough On People With Type 2 Diabetes, Study Says

MONDAY, March 30, 2026 — Folks working a night shift have a harder time managing their type 2 diabetes, a new study says. Health care workers with diabetes – mainly...

TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts

TUESDAY, March 24, 2026 — TrumpRx, the president's discount program for prescription drugs, is adding three more products to its site as it continues efforts to lower drug...

Insulin Prices Fell For Medicare Patients Under Biden-Era Caps, Study Finds

TUESDAY, March 24, 2026 — Biden-era policies have reined in insulin prices for Medicare patients, a new study says. Roughly 3 out of 4 (75%) Medicare prescription...

More news resources

FDA Medwatch Drug Alerts

Daily MedNews

News for Health Professionals

New Drug Approvals

New Drug Applications

Drug Shortages

Clinical Trial Results

Generic Drug Approvals

Drugs.com Podcast

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Posted : 2026-04-08 09:03

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.